

ePCTs in Context

Small Group Work and Panel Discussion With NIH Collaboratory Trial Investigators

Moderator:

Emily C. O'Brien, PhD

Associate Professor in Population Health Sciences

Duke University School of Medicine



**NIH PRAGMATIC TRIALS
COLLABORATORY**

Rethinking Clinical Trials®

Learning goals



- Hear a brief description of the NIH Collaboratory Trials being used as case studies for the small group activity
- Small group discussion
 - Breakout into small groups
 - Each group discusses 1 question
 - Report back to the group
- Panelists discuss how they handled the challenges
- Reflect on the challenges, solutions, and lessons learned, to include Q&A

NIH Collaboratory Trial panelists

- Diana Burgess, PhD — RAMP
- Julie Fritz, PT, PhD, ATC — BeatPain Utah
- Vince Mor, PhD — PROVEN
- David W. Wetter, PhD — LungSMART

Small group discussion

- **BeatPain Utah**

- During pilot phase, COVID-19 pandemic made in-person meetings at partnering clinics impossible and limited the availability of staff to participate in training. How would you implement the e-referral process and ensure the project could reach enough potential participants?

- **LungSMART**

- Trial requires new practice model for primary care association and community health centers, with liability insurance to be covered by the association and access to EHRs by the registered nurse across multiple community health center systems. How would you overcome this problem?

- **PROVEN**

- Because of inadequate compliance in the intervention facilities, study team added “personal touch” with monthly calls. Even so, only 30% to 40% of facilities engaged, 30% intermittently engaged, and 20% were noncompliant. How would you address this challenge?

- **RAMP**

- Changes in partnering healthcare system environment will create challenges in working with stakeholders to cocreate strategies to overcome barriers to national implementation. How would you approach this problem?

Reflection on today's topics



- ePCTs and hybrid effectiveness-implementation trials
- Design, analysis, and monitoring considerations
- Measuring effectiveness and implementation outcomes